Among the two thirds of cases of childhood ALL classified as early pre-B, an increased leukemic cell burden (ie, hyperleukocytosis and high serum lactic dehydrogenase level), ages less than 1 and greater than 10 years, black race, DNA index less than 1.16, pseudodiploidy, hypodiploidy, and lack of common ALL antigen (CALLA) expression have each been associated with a poorer treatment outcome.'-* Within the category of pre-B leukemia, which comprises approximately 20% of cases of childhood ALL, black race, male gender, age of less than 1 or more than 10 years, high serum lactic dehydrogenase level, pseudodiploidy, and chromosomal translocation were found to confer an increased risk of treatment fail~re.'~'' For the 1% to 2% of patients with B-cell ALL, those with a high serum lactic dehydrogenase level or central nervous system (CNS) leukemia have an especially poor prognosis."
and CDlO in 35%. Four presenting features were found to confer an increased risk of treatment failure: age 2 1 5 years, L2 lymphoblast morphology, abnormal karyotype, and membrane CD3 expression. This study illustrates the heterogeneity of presentations of childhood T-cell ALL and suggests that the relative importance of risk factors in ALL differs according to immunophenotype and treatment strategy. 0 1990 by The American Society of Hematology.
a mediastinal mass, and CNS leukemia often characterize this
Children with T-cell ALL generally have a poorer prognosis than those with B-precursor ALL,I2-l6 although in one recent clinical trial'' demonstrating improved outcome in patients treated with intensified chemotherapy, the T-cell phenotype was not found to have prognostic importance. Attempts to identify subsets of T-cell cases with prognostic relevance have been sporadic and largely u n s u c c e s s f~l . '~~~~ Therefore, we sought to define the heterogeneity of clinical and biologic features in a cohort of 120 consecutive children with T-cell ALL and to assess their value as predictors of failure-free survival.
MATERIALS AND METHODS
From May 1979 to September 1988, 805 consecutive children with newly diagnosed ALL were admitted to St Jude Children's Research Hospital, Memphis, TN. Of the 790 cases with complete blast cell immunophenotyping, 120 (15%) were T-cell ALL. The ages of these 84 boys and 36 girls at diagnosis ranged from 1.7 to 18.8 years (median, 10.3 years), and their leukocyte counts ranged from 1.7 to 1,070 x 109/L (median, 100 x 109/L).
All patients were subjects of two Total Therapy studies (X and XI). 24325 The 55 patients in the earlier study received teniposide plus cytarabine twice weekly immediately before and after a conventional 4-week induction course of prednisone, vincristine, and L-asparaginase; continuation therapy consisted of 2.5 years of 6-mercaptopurine and methotrexate, with five 2-week pulses of teniposide and cytarabine given every 10 weeks during the first year. Periodic intrathecal methotrexate and delayed cranial irradiation (2,400 cGy at 1 year) were administered as CNS prophylaxis. The 65 patients in the latter study received induction treatment with prednisone, vincristine, daunorubicin, L-asparaginase, teniposide, cytarabine, and high-dose methotrexate. Continuation therapy for 120 weeks consisted of four pairs of drugs: etoposide plus cyclophosphamide, 6-mercaptopurine plus methotrexate, teniposide plus cytarabine, and prednisone plus vincristine. Intermittent intrathecal methotrexate, hydrocortisone, and cytarabine, and delayed cranial irradiation (1,800 cGy at 1 year or 2,400 cGy for patients with CNS leukemia) were administered to prevent CNS relapse. Leukapheresis or exchange transfusion was performed in patients with a leukocyte count 2200 x 109/L at diagnosis. Informed consent was obtained for all patients, and the investigations were approved by the institution's clinical trials review committee.
Leukemic blast cells from bone marrow aspirates were separated on a Ficoll-Hypaque gradient. Cell surface Blast cell phenotyping. Time-to-failure, defined as the interval between remission and relapse or death due to any cause, was analyzed by the Kaplan-Meier procedure.'* (Early death or failure to enter remission was considered a failure at zero time.) Differences in failure-free survival were compared by the logrank testz9 or the Cox regression analysi~.~' Effect of potentially independent prognostic factors on time-to-failure was tested by two methods: Cox regression" and recursive partitioning." The Cox proportional hazards model permits comparison of treatment outcome for subsets of patients while simultaneously adjusting for the effect of other factors (covariates). A stepwise selection procedure was used to determine factors that were significantly related to time-to-failure. At each step of the analysis, the factor with the smallest P value was added to the multivariate model until the P value exceeded .lo. The recursive partitioning method accounts for the interactions between significant variables and is less affected by missing data than is the Cox regression analysis. At each step of the procedure a split was made using the variable with the most significant P value by logrank test. After each split, subgroups were amalgamated if the difference between them was not significant (P > .05) by the logrank test.
Sfatisfical analysis.

RESULTS
Presenting features of the 120 patients with T-cell ALL
are summarized in Table 1 . CNS leukemia was present in 12.5% of the patients and a mediastinal mass in 61%. The blast cell morphologic type was FAB L2 in 32% of the cases. Hyperdiploidy >50 or a DNA index 21.16 was remarkably rare. Abnormal clones could not be detected in 26% of the cases. Forty-one (46%) of 89 banded cases had a translocation. E-rosette formation by leukemic blasts was found in 43% of the cases. Of 86 cases tested with a panel of T-cell-associated MoAbs, 38% showed expression of CD 1, 33% CD3,50% CD4,94% CD5,55% CD8, and 35% CD10. An estimated 46 f 17% (2SE) of these T-cell cases compared with 59 * 3% of the non-T-cell cases attained 5 years of failure-free survival (P = .0005).
Because the distribution of presenting characteristics and the outcome of therapy for T-cell cases did not differ significantly between studies X and XI, we elected to combine these two groups for analysis of prognostic factors. When times-to-failure were analyzed by the logrank test, several presenting features were found to be associated with a poorer treatment outcome: age 2 15 years, French-AmericanBritish (FAB) L2 morphology, abnormal karyotype, and membrane CD3 expression (Table 1) . Notably, leukocyte count had no prognostic significance, whether it was analyzed as continuous variable or categorical variable using different cut points.
In the Cox proportional hazards model that included all clinical features, age 2 1 5 years and L2 morphology were independently associated with a poor prognosis ( Table 2) . Sixty percent of patients with age less than 15 years and blast cells of L1 morphology, compared with 20% of all other patients, are expected to remain disease-free for 5 years (P < .0001, Fig 1) . The same multivariate analysis was performed for a subset of patients (n = 78) with detailed karyotypic and immunophenotypic studies. The presenting features and treatment outcome did not differ between these 78 patients and the 42 patients excluded from the analysis (data not shown). In this multivariate analysis, abnormal karyotype, membrane CD3 expression, and L2 morphology emerged as independent risk factors ( Table 3) . As depicted in Fig 2, cases with a n abnormal karyotype and CD3 expression had the worse prognosis, whereas those with an abnormal karyotype but lacking membrane CD3 expression had an intermediate prognosis. Cases with a normal karyotype had the best treatment outcome. Of the two patients whose blast cells had an abnormal karyotype, membrane CD3 expression, and L2 morphology, one failed induction therapy and the other relapsed within 3 months.
Results of recursive partitioning analysis disclosed the same four presenting features to have prognostic significance (Fig 3) . As shown, age was the best predictor, with less than 15 years being a favorable factor. Among patients younger than 15 years, cases with L1 morphology fared significantly better than those with L2 morphology. In the subgroup with age less than 15 years and L1 morphology, the 30 cases lacking blast cell membrane CD3 had a better outcome than the 19 cases with the antigen expression. Of the 72 cases that were amalgamated into one group, the 11 with normal karyotype had a better prognosis than the others. Thus, by recursive partitioning, cases can be divided into three prognostic groups: good (age less than 15 years, L1 morphology, and CD3-phenotype), intermediate (others with normal karyotype), and poor (others with abnormal karyotype).
DISCUSSION
This study demonstrates that age 2 1 5 years, FAB L2 morphology, abnormal leukemic cell karyotype, and blast cell CD3 expression predict a poor outcome of therapy in children with T-cell ALL. Notably, a large leukemic cell burden, as reflected by hyperleukocytosis, high serum lactic dehydrogenase level, or massive liver or spleen size did not appear to influence prognosis, whether these features were analyzed as continuous variables or categorical variables. This finding contrasts with a study by Pullen et all9 in which hyperleukocytosis emerged as the strongest adverse risk factor in children with T-cell ALL. Use of leukapheresis or exchange transfusion for the 32 patients with hyperleukocytosis (2200 x 109/L) and intensified chemotherapy in our two clinical trials may have led to more rapid and more complete reduction of the initial blast cell population, resulting in loss of the prognostic significance usually associated with high leukocyte counts. These cytoreductive procedures, by removing an average of 1 x loi2 leukocytes per pr~cedure,'~ not only can reduce the morbidity and mortality from blast Factors analyzed included age, FAB classification, treatment protocol, gender, race, CNS leukemia, liver and spleen size, leukocyte count, hemoglobin level, platelet count, serum lactic dehydrogenase level, €-rosette formation, and mediastinal mass. One patient was excluded because of incomplete data.
'Hazard ratio gives the estimated proportional increase in the risk of treatment failure at any given time for a patient with the worse risk feature relative to one without the risk factor. This ratio was adjusted for the confounding effect of other variables.
tStepwise regression analysis was used to identify significant predictors of treatment outcome. Significance levels were adjusted for the competing effects of covariates entered in the Cox model. cell lysis but may decrease the population of relatively drug-resistant cells and the number of blast cells likely to develop resistance.
Age a t diagnosis is a consistently reliable predictor of outcome in childhood ALL. Patients more than 10 years or less than 1 year old fare much worse than children in the intermediate age g r o~p s .~,~,~,~~-~~ In one study among cases of T-cell ALL, children with age more than I1 years fared significantly worse than those between 1.5 and 11 year^.'^ We found age more than 15 years to be associated with an even worse prognosis among adolescents (more than 10 years of age) with ALL.36 We now extend our previous finding to patients with T-cell disease.
Studies of the prognostic importance of L2 morphology in childhood ALL have yielded controversial results. In a Pediatric Oncology Group study,37 there was no correlation between L1 or L2 morphology and immunologic markers, risk group, or prognosis. However, investigators in the Childrens Cancer Study group found L2 morphology to be associated with a worse prognosis in children with non-B-cell ALL.38 Our findings are in agreement with the latter report and extend it by showing the prognostic importance of L2 Explanation of the analysis is provided in the footnotes to Table 2 . Additional factors analyzed were ploidy group, chromosomal translocation, and CDl, CD3, CD4, CD8, and CDlO expression.
*Includes one case with hyperdiploidy >50.
morphology in patients with T-cell ALL. Additional study is needed to clarify the biologic significance of this risk factor. Reinherz et a139*40 have proposed a three-stage scheme of intrathymic maturation based on changes in the expression of surface antigens. With this system, most T-cell malignancies can be subclassified as representing the early, intermediate, or mature thymocyte stage of differentiati~n.'~.~~ Several studies have failed to disclose any important differences in clinical features or treatment outcome among the three phenotypically defined subgroup^.^^^^^ Although early thymocyte stage was linked to a lower remission induction rate in one analysis, the overall treatment outcome did not differ among the three stages of disease." By contrast, we show that cases with expression of surface CD3 antigen, corresponding to the mature-stage phenotype, had a significantly poorer treatment outcome than did cases with blasts lacking CD3 expression. The basis for this conflicting result is unclear, but may relate to differences in treatment regimens.
With improved cytogenetic techniques, over 90% of cases of ALL are now identified as having clonal chromosome abn~rmalities.~' Despite this advance, one fourth of T-cell cases still do not have detectable leukemic cell chromosomal abnormalities. The high proportion of normal karyotypes could reflect dividing residual non-neoplastic marrow elements in cases in which leukemic metaphase cells cannot be easily obtained. It is also possible that the chromosomal abnormalities are subtle and not readily appreciated. Alternatively, the genetic changes may be submicroscopic, requiring molecular approaches for detection. It is of interest that normal karyotypes are found more often in T lymphoblasts in correlated with a favorable outcome in this study. The rarity of hyperdiploidy >SO, a favorable prognostic sign in Bprecursor ALL,4' precluded its evaluation as a favorable risk factor in T-cell ALL.
Expression of CDlO (CALLA), a glycoprotein with a structure identical to that of human membraneassociated neutral endopeptida~e,4~-~ was found in 27% of the childhood T-cell cases studied by Dowell et aln and in 35% of the T-cell cases we investigated. However, in contrast to Dowell et a1 we did not find CDlO expression to be significantly associated with a favorable outcome in T-cell ALL.
In summary, we have shown that the importance of clinical and biologic prognostic features in ALL depends on both immunophenotype and therapy.'*'* Our findings extend those previously reported for children with T-cell ALL by showing an adverse prognostic effect of FAB L2 morphology, membrane CD3 expression, and abnormal leukemic cell karyotype. Further studies should determine if any particular karyotypic alterations exert an adverse influence on prognosis. Because our patients received two different treatments and the patient sample with complete biologic data is relatively small for multivariate analysis, additional studies are needed to confirm the prognostic significance of the variables identified in this study.
